SJJ received grants from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion Healthcare, Daewoong, Green Cross Laboratories, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, and UCB and personal fees for lectures or consultation from AbbVie, Boehringer Ingelheim (including a portion related to Asian epidemiology and treatment guidelines of GPP), Daewoong, Eli Lilly and Company, Janssen Pharmaceuticals, Kolon Pharma, LEO Pharma, Novartis, Sanofi, and Yuhan. RJC received research funding from Sun Pharma, Leo Pharma, Bristol Myers Squibb, Regeneron, and Janssen. Unless stated these competing interests are unrelated to treatments for GPP.